Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Amunix Pharmaceuticals Inc. is currently navigating 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are being reviewed by 3 distinct examiners, which introduces a variety of individual examination styles into the company's prosecution pipeline. Despite the variety of examiners, the work is concentrated within 2 distinct art units, suggesting that the underlying technologies share significant commonalities in their classification.
The busiest examiner identified in the data is JUEDES, AMY E, who is responsible for 1 pending office action. Because each of the 3 pending office actions is assigned to a different examiner, the company faces a decentralized prosecution environment where each matter may progress at a different pace. This arrangement requires the applicant to manage three separate examiner relationships simultaneously, even though the busiest examiner_pending count is only 1. This distribution provides the company with multiple perspectives on their biological innovations.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 2 (67%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JUEDES, AMY E | 1 | 44.8% | +41.7% |
| DENT, ALANA HARRIS | 1 | 44.2% | +32.0% |
| WU, JULIE ZHEN QIN | 1 | 62.0% | +50.7% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18073935 | CYTOKINE CONJUGATES | DENT, ALANA HARRIS | 25d overdue |
| 18064253 | HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME | JUEDES, AMY E | — |
| 17621993 | CD3 ANTIGEN BINDING FRAGMENTS AND COMPOSITIONS COMPRISING SAME | WU, JULIE ZHEN QIN | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1644 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18064253 | HER-2 TARGETED BISPECIFIC COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME | JUEDES, AMY E | 1644 | §112DP | Final Rejection | — | Pending | Dec 10, 2022 |
| 18073935 | CYTOKINE CONJUGATES | DENT, ALANA HARRIS | 1643 | §103 | Final Rejection | 25d overdue | Pending | Dec 02, 2022 |
| 17621993 | CD3 ANTIGEN BINDING FRAGMENTS AND COMPOSITIONS COMPRISING SAME | WU, JULIE ZHEN QIN | 1643 | §112DP | Final Rejection | — | Pending | Dec 22, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial